Literature DB >> 22333371

Validation of the triaxial accelerometer for the evaluation of physical activity in Japanese patients with COPD.

Masae Kanda1, Yoshiaki Minakata, Kazuto Matsunaga, Hisatoshi Sugiura, Tsunahiko Hirano, Akira Koarai, Keiichiro Akamatsu, Tomohiro Ichikawa, Masakazu Ichinose.   

Abstract

OBJECTIVE: The quantification of physical activity is useful for the management of chronic obstructive pulmonary disease (COPD) but has not been fully established yet. The DynaPort Activity Monitor(®) (DAM), a triaxial accelerometer is the only well validated accelerometer in Caucasians but it has not been validated in Japanese COPD patients. We initially evaluated the reproducibility of the DAM in Japanese healthy subjects. Next, the within-subject repeatability and the determinants of physical activity were investigated in Japanese COPD patients.
MATERIALS AND METHODS: The durations of locomotion, standing, and sitting measured by the DAM were compared to those of the self-records (Study 1). COPD patients wore the DAM for 3 days and the durations of each activity of 2 selected days were compared to assess the repeatability (Study 2). The relationship between the duration of locomotion and the physiological properties were examined (Study 3).
RESULTS: The activities measured by the DAM were significantly associated with those of the self-records (p<0.001). The values of the intra-class correlation coefficient (ICC) for the reproducibility were over 0.99, and the agreement with the self-records was observed for the DAM. Similarly, the values of ICC for repeatability were over 0.84 in all activities, and there was no systematic bias in the COPD patients. The duration of locomotion was negatively correlated with the total lung capacity (TLC) and closing capacity/TLC, but not with other pulmonary functions, exercise capacity, muscle force, dyspnea, or modified BODE index.
CONCLUSION: The triaxial accelerometer is reliable for evaluating the physical activity of Japanese COPD patients.

Entities:  

Mesh:

Year:  2012        PMID: 22333371     DOI: 10.2169/internalmedicine.51.6441

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  The impact of pulmonary rehabilitation on severe physical inactivity in patients with chronic obstructive pulmonary disease: a pilot study.

Authors:  Mimi Thyregod; Anders Løkke; Uffe Bodtger
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-10-12

2.  Linguistic Validation of the Japanese Version of the Multidimensional Dyspnea Profile and Relation to Physical Activity in Patients with COPD.

Authors:  Masashi Kanezaki; Akira Tamaki; Kunihiko Terada; Satoru Ebihara
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-01-21

Review 3.  Quality Evaluation of Free-living Validation Studies for the Assessment of 24-Hour Physical Behavior in Adults via Wearables: Systematic Review.

Authors:  Marco Giurgiu; Irina Timm; Marlissa Becker; Steffen Schmidt; Kathrin Wunsch; Rebecca Nissen; Denis Davidovski; Johannes B J Bussmann; Claudio R Nigg; Markus Reichert; Ulrich W Ebner-Priemer; Alexander Woll; Birte von Haaren-Mack
Journal:  JMIR Mhealth Uhealth       Date:  2022-06-09       Impact factor: 4.947

Review 4.  Functional Status Assessment of Patients With COPD: A Systematic Review of Performance-Based Measures and Patient-Reported Measures.

Authors:  Yang Liu; Honghe Li; Ning Ding; Ningning Wang; Deliang Wen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

5.  Differences in physical activity according to mMRC grade in patients with COPD.

Authors:  Atsushi Hayata; Yoshiaki Minakata; Kazuto Matsunaga; Masanori Nakanishi; Nobuyuki Yamamoto
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-13

Review 6.  Coherence between self-reported and objectively measured physical activity in patients with chronic obstructive lung disease: a systematic review.

Authors:  Mimi Thyregod; Uffe Bodtger
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.